Chronic myeloid leukaemia: why some patients with don’t respond to therapy

 Podcast: Research Pulse, Episode 07.

Today we’re focusing on chronic myeloid leukaemia (CML) and research which is solving the problem of why some patients don’t respond to therapy.

We’re speaking to Professor Susan Branford from SA Pathology and the Centre for Cancer Biology, an alliance between SA Pathology and the University of South Australia.

We learn:

  • about the game-changing use of targeted drug therapy for CML
  • that about 20% of patients with CML are resistant to targeted drug therapy
  • about using next-generation sequencing to find the genetic mutations associated with drug resistance

Listen and subscribe

To listen to upcoming episodes, find us and subscribe wherever you get your podcasts.

Subscribe to Research Pulse.


Get in touch

We would love to get your feedback! You can do this in a number of ways.

In your app of choice (e.g. Spotify, Apple Podcasts):

  • leave a comment
  • leave a rating

On socials:

  • share the podcast with your colleagues and friends

By email:


More about the research

Click here to read the published work mentioned in this episode.


About the researcher

Professor Branford is Head of the Leukaemia Unit in the Department of Genetics and Molecular Pathology at SA Pathology and a Section Leader at the Centre for Cancer Biology, University of South Australia.

Her research focusses on understanding the mechanisms of drug resistance and she leads the International CML Genomics Alliance. The Alliance aims to establish a genomically-based risk classification system to enhance patient management.

She received the 2021 Rowley Prize from the International CML Foundation for significant contribution to the understanding of the biology of chronic myeloid leukaemia.